Moleculin Hosted Virtual AML Clinical Day Featuring Clinicians Martin S. Tallman, MD and Michael Andreeff, MD, PhD
Better
Treatments,
More Tomorrows
Better
Treatments,
More Tomorrows
We Are
Advancing
a growing pipeline of product candidates for the treatment of highly resistant cancers and viruses.
![HEX1_V2](https://moleculin.com/wp-content/uploads/2022/04/HEX1_V2.png)
![Hex2_Final](https://moleculin.com/wp-content/uploads/2022/04/Hex2_Final.png)
Innovative
Therapies
through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.
Innovative
Therapies
through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.
![Hex2_Final](https://moleculin.com/wp-content/uploads/2022/04/Hex2_Final.png)
The Annamycin Opportunity
Presented by CEO, Walter Klemp
The Moleculin Opportunity
A Three-Part Series Presented by CEO, Walter Klemp
Part 1:
Recent Progress and Emphasizes the Potential Value of Annamycin
Priority Development Pipeline
![MBRX_Pipe3.2.26.24](https://moleculin.com/wp-content/uploads/2024/02/MBRX_Pipe3.2.26.24.png)
AML Patient Journey and the Annamycin Opportunity
Latest Releases
Stock Information
NASDAQ: MBRX
NASDAQ: MBRX
Corporate
Presentation
Corporate
Presentation